2026 Annual Report & Appendix 4E
Filed with ASX · · 81 pages · English
Summary by 6ix AI
The report indicates a significant increase in income from ordinary activities, while the company reported a substantial loss attributable to its ongoing research and development efforts. The company has made progress in its clinical trials and technology transfer related to its StemSmart™ platform, which is aimed at treating neurodegenerative conditions. No dividends were declared during the reporting period, reflecting the company's focus on development rather than immediate returns to shareholders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- Remarkable Results from Patients treated with StemSmart
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Clinical Results Achieved under Special Access
- Trading Halt
Later from Neuroscientific Biopharmaceuticals
All Neuroscientific Biopharmaceuticals news releasesFollow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals